SRCM
INDV icon

Sage Rock Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Sage Rock Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$385K Buy
39,500
+27,000
+216% +$316K 1.73% 20
2024
Q2 		$202K Buy
+12,500
New +$226K 0.76% 26

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return

Sage Rock Capital Management's INDV Position: Q3 2024 in Review

Sage Rock Capital Management increased its Indivior Pharmaceuticals (INDV) stake by 216% in Q3 2024, buying an estimated $316K and bringing the position to 39,500 shares worth $385K. The position accounts for 1.73% of the portfolio, ranked #20.

Sage Rock Capital Management first reported a position in INDV in Q2 2024 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold INDV as of Q3 2024.

  • Sage Rock Capital Management held 39,500 shares of Indivior Pharmaceuticals worth $385K as of Q3 2024.
  • Sage Rock Capital Management bought 27,000 Indivior Pharmaceuticals shares in Q3 2024, an estimated $316K.
  • Indivior Pharmaceuticals made up 1.73% of Sage Rock Capital Management's portfolio in Q3 2024, its #20 holding.
  • Sage Rock Capital Management first reported a position in Indivior Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2024.

Based on Sage Rock Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.